148 related articles for article (PubMed ID: 14977214)
41. The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders.
Kandanearatchi A; Brew BJ
FEBS J; 2012 Apr; 279(8):1366-74. PubMed ID: 22260426
[TBL] [Abstract][Full Text] [Related]
42. Vitamins B2 and B6 as determinants of kynurenines and related markers of interferon-γ-mediated immune activation in the community-based Hordaland Health Study.
Theofylaktopoulou D; Ulvik A; Midttun Ø; Ueland PM; Vollset SE; Nygård O; Hustad S; Tell GS; Eussen SJ
Br J Nutr; 2014 Oct; 112(7):1065-72. PubMed ID: 25105221
[TBL] [Abstract][Full Text] [Related]
43. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.
Bose S; Cho J
Arch Pharm Res; 2013 Sep; 36(9):1039-50. PubMed ID: 23771498
[TBL] [Abstract][Full Text] [Related]
44. Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.
Jiao X; Ashtari N; Rahimi-Balaei M; Chen QM; Badbezanchi I; Shojaei S; Marzban A; Mirzaei N; Chung S; Guan T; Li J; Vriend J; Mehr SE; Kong J; Marzban H
Curr Mol Pharmacol; 2017; 10(2):115-140. PubMed ID: 26758948
[TBL] [Abstract][Full Text] [Related]
45. The Wnt signaling pathway as a target for the treatment of neurodegenerative disorders.
Terstappen GC; Gaviraghi G; Caricasole A
IDrugs; 2006 Jan; 9(1):35-8. PubMed ID: 16374731
[TBL] [Abstract][Full Text] [Related]
46. Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease.
Majewski M; Kozlowska A; Thoene M; Lepiarczyk E; Grzegorzewski WJ
J Physiol Pharmacol; 2016 Feb; 67(1):3-19. PubMed ID: 27010891
[TBL] [Abstract][Full Text] [Related]
47. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.
Bari M; Rapino C; Mozetic P; Maccarrone M
Exp Neurol; 2010 Jul; 224(1):74-84. PubMed ID: 20353779
[TBL] [Abstract][Full Text] [Related]
48. [Role of drug transporters in the central nervous system].
Erdő F; Temesszentandrási-Ambrus C; Beéry E
Orv Hetil; 2016 Mar; 157(10):370-8. PubMed ID: 26920327
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of photostability in kynurenines: a joint electronic-structure and dynamics study.
Tuna D; Došlić N; Mališ M; Sobolewski AL; Domcke W
J Phys Chem B; 2015 Feb; 119(6):2112-24. PubMed ID: 25054917
[TBL] [Abstract][Full Text] [Related]
50. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Gray SG; Dangond F
Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
[TBL] [Abstract][Full Text] [Related]
51. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species.
Giles GI; Collins CA; Stone TW; Jacob C
Biochem Biophys Res Commun; 2003 Jan; 300(3):719-24. PubMed ID: 12507509
[TBL] [Abstract][Full Text] [Related]
52. Kynurenine metabolism in Alzheimer's disease.
Baran H; Jellinger K; Deecke L
J Neural Transm (Vienna); 1999; 106(2):165-81. PubMed ID: 10226937
[TBL] [Abstract][Full Text] [Related]
53. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
54. Kynurenines and anxiety.
Lapin IP
Adv Exp Med Biol; 1996; 398():191-4. PubMed ID: 8906265
[No Abstract] [Full Text] [Related]
55. Proteomics-driven progress in neurodegeneration research.
Fountoulakis M; Kossida S
Electrophoresis; 2006 Apr; 27(8):1556-73. PubMed ID: 16555340
[TBL] [Abstract][Full Text] [Related]
56. Multi-target-directed ligands to combat neurodegenerative diseases.
Cavalli A; Bolognesi ML; Minarini A; Rosini M; Tumiatti V; Recanatini M; Melchiorre C
J Med Chem; 2008 Feb; 51(3):347-72. PubMed ID: 18181565
[No Abstract] [Full Text] [Related]
57. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms.
Pannu R; Singh I
Neurochem Int; 2006 Jul; 49(2):170-82. PubMed ID: 16765486
[TBL] [Abstract][Full Text] [Related]
59. [Neuronal growth factors--neurotrophins].
Meyer M; Rasmussen JZ
Ugeskr Laeger; 1999 Apr; 161(14):2063-70. PubMed ID: 10354791
[TBL] [Abstract][Full Text] [Related]
60. NCAM in neuropsychiatric and neurodegenerative disorders.
Brennaman LH; Maness PF
Adv Exp Med Biol; 2010; 663():299-317. PubMed ID: 20017030
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
